Amgen Inc. buy melinda
Start price
31.08.17
/
50%
€176.34
Target price
12.09.17
€190.00
Performance (%)
7.96%
End price
12.09.17
€190.38
Summary
This prediction ended on 12.09.17 with a price of €190.38. The BUY prediction by melinda finished with a performance of 7.96%. melinda has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Amgen Inc. | -1.948% | -1.948% | 36.845% | 38.051% |
iShares Core DAX® | -0.205% | 2.949% | 17.330% | 18.203% |
iShares Nasdaq 100 | 1.613% | 5.877% | 37.451% | 56.281% |
iShares Nikkei 225® | -0.740% | -1.256% | 11.847% | 5.531% |
iShares S&P 500 | 0.267% | 3.240% | 29.308% | 46.371% |
Comments by melinda for this prediction
In the thread Amgen Inc. diskutieren
$
Wenn in Phase III getestet Kopf an Kopf, das Bestreben, reduziert KYPROLIS und Dexamethason das Sterberisiko um 21% und erhöhte die Überlebenszeit von 7,6 Monaten im Vergleich zu Velcade und Dexamethason in Patienten mit rezidivierendem oder refraktärem multiplem Myelom
(Zielkurs erreicht)